CAMBRIDGE, UNITED KINGDOM--(Marketwire - November 16, 2007) -
BioWisdom has launched an exclusive program that gives access to its
OmniViz visualization and analysis software to academics and
not-for-profit organisations at a heavily discounted price of $999.
"In the last few years BioWisdom has created a world class capability
for providing healthcare intelligence to the pharmaceutical
industry," said Gordon Baxter, CEO. "The core of this strategy has
been and remains the rapidly emerging field of ontology as applied to
life sciences research and development, delivered through BioWisdom's
proprietary platform Sofia. BioWisdom is now preparing to enter the
next stage of its growth, bringing the value of this leadership in
life sciences ontology to the desktops of individual scientists
globally through both of the recently acquired technologies, SRS and
OmniViz."
"OmniViz can analyze extremely large collections of experimental,
numerical, categorical, genomic or chemical data, and analyze
internal and external literature, patents and competitive
intelligence information," added Dr Michael R Stapleton, BioWisdom's
Chief Business Officer. "It provides a unique ability to discover,
prioritize and test decisions and hypotheses. As part of BioWisdom's
long standing collaboration and commitment to the academic and
not-for-profit organizations and building on the similar program in
place for BioWisdom's bioinformatics platform SRS, we are pleased to
be able to make the full power of OmniViz available to the global
academic community with the announcement of this exciting program."
For more information about OmniViz, including purchasing an academic
licence, please visit www.biowisdom.com/content/omniviz.
Notes to Editors
ABOUT BIOWISDOM
BioWisdom delivers intelligence for the Healthcare Industry and helps
clients to navigate the complex scientific and commercial issues
involved in developing successful healthcare products. The company
provides a powerful suite of software tools for the acquisition,
integration, visualization and high value analysis of healthcare
intelligence. The BioWisdom team combines extensive experience of the
pharmaceutical and biotechnology industries with proven expertise in
life science software development.
For further information please visit www.biowisdom.com
Contacts:
BioWisdom Ltd
Gordon Baxter
CEO
Tel: +44 (0)1223 874800
Email: info@biowisdom.com
Website: http://www.biowisdom.com
BioWisdom Ltd
Mike Stapleton
Chief Business Officer
Tel: +44 (0)1223 874800
Email: info@biowisdom.com
Website: http://www.biowisdom.com
The Hogarth Partnership
Sarah Richardson / Melanie Toyne Sewell
Tel: +44 (0)207 357 9477
